IPO
IPO filing, visualized

Bambusa Therapeutics, Inc.

BBTX · Nasdaq424B4 · Oct 30, 2026Priced Oct 29, 2026

Priced Oct 29, 2026 · range was $15–$17 · latest SEC filing Nov 6, 2026.

Pinch-zoom for details.

The offering

Final price
$16.00
per share, from the final prospectus
Shares offered
10.6M
sold by the company
Raise at the final price
$169M
10,555,555 × $16, before fees

What the company does

Clinical-stage drug developer working on long-acting bispecific antibodies for immunology and inflammation.

Operating result

Fiscal year

1st half

Net result

Fiscal year

1st half

Things to weigh

  • Loss-making: net loss of $22.4M in H1 2026.

The numbers

$Period 2024FY2025YoYH1 2025H1 2026Change
Operating result(13.9M)(44.0M)n/m(15.4M)(24.1M)−55.7%
Net result(13.7M)(41.1M)n/m(14.7M)(22.4M)−51.6%
$Period 2024FY2025YoY
Operating result(13.9M)(44.0M)n/m
Net result(13.7M)(41.1M)n/m
$H1 2025H1 2026Change
Operating result(15.4M)(24.1M)−55.7%
Net result(14.7M)(22.4M)−51.6%

Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.

Risks

  1. We have a limited operating history, which may make it difficult for you to evaluate our current business and predict our future success and viability
  2. Since our formation, we have incurred, and anticipate that we will continue to incur, significant losses…
  3. We face substantial competition, including from other biotechnology and pharmaceutical companies, who may discover, develop…
  4. Our business depends entirely on the success of our product candidates, and we cannot guarantee…
  5. Even if any of our product candidates receives regulatory approval, such product may fail to achieve market acceptance by physicians, patients…

The filing's own risk-factor headings, shortened.

Strategy

  1. Advance a Portfolio of Bispecific Antibodies Targeting High-Value I&I Indications by Synergistically Combining Multiple Clinically…
  2. Continue to Advance Our Lead Product Candidate, BBT001, through Ongoing Clinical Development in AD and CSU and Pivotal Development Activities in AD
  3. Continue to Advance our Second Lead Product Candidate, BBT002, through Clinical Development in COPD, CRSwNP, and Asthma

The filing's own strategy headings, shortened.

Source: Bambusa Therapeutics, Inc.'s Form 424B4, filed with the SEC on Oct 30, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.